AbbVie is a leading pharmaceutical company with a strong history and a diverse portfolio of products. The company's flagship product, Humira, has generated significant revenue and it has a pipeline...

AbbVie is a high-yield dividend stock that packs a punch. Stryker is a well-rounded business.

Dividend Kings are the most battle-tested dividend payers on Wall Street, with AbbVie being just one of four in the healthcare sector. The pharmaceutical's 4% dividend yield is covered by both earn...

AbbVie (ABBV) concluded the recent trading session at $147.23, signifying a -0.49% move from its prior day's close.

Since its spin-off from Abbott Labs, AbbVie has delivered outstanding performance, surpassing both its parent company and the S&P 500, thanks to the success of Humira. In 2022, AbbVie became the se...

AbbVie boasts a stellar dividend track record and a resilient business. Eli Lilly's dividend yield might be low, but there's a lot more to the story.

Of the 500 stocks listed in the benchmark S&P 500 index, only 51 (10%) are considered dividend kings and have increased their dividend payout to stockholders for 50 consecutive years or longer. Div...

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.

Paul Tudor Jones told CNBC this week that the bond market could push interest rates higher and cause a recession. He believes that the stock market will fall quite a bit before this predicted reces...

Nervous investors are turning to defensive stocks, and there's plenty of reason to be among their ranks. The U.S. Federal Reserve's continuing battle to control inflation is the primary reason cata...

Dividend stocks have proved time and again to be a superior investing strategy. We all want capital appreciation, or to see our stocks grow in value over time, but dividends are what really drive e...

In the most recent trading session, AbbVie (ABBV) closed at $149.11, indicating a +0.59% shift from the previous trading day.

With bond yields near historic highs in many instances, stock prices have softened at the onset of Q4. Even so, dividend stocks are still likely to outperform most other asset classes in both the s...

AbbVie has an impressive streak of consecutive dividend increases. Its underlying business is solid despite one current challenge.

Dividend investing will always stay in style. While the market moves in cycles of ups and downs, dividend investing offers income even during prolonged market downturns.